(Q33865065)

29 July 2017

1 reference

title

Antibiotic efficacy in vivo predicted by in vitro activity (English)

1 reference

29 July 2017

Mattie H

1

1 reference

29 July 2017

1 March 2000

1 reference

International Journal of Antimicrobial Agents

29 July 2017

1 reference

29 July 2017

14

1 reference

29 July 2017

2

1 reference

29 July 2017

91-98

1 reference

A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Kinetics of pharmacologic response

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Cefazolin and Cephradine: Relationship between Antibacterial Activity in Vitro and in Mice Experimentally Infected with Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Biphasic kinetics of bacterial killing by quinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Mathematical model for comparison of time-killing curves

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

A Paradoxical Zone Phenomenon in the Bactericidal Action of Penicillin in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

The Antibacterial Activity of Combinations of Mecillinam and Ampicillin in Vitro and in Normal and Granulopenic Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

The relative potency of amoxycillin and ampicillin in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

The relation between plasma and tissue concentrations of antibiotics. Description of a method.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Effectiveness of netilmicin and tobramycin against Pseudomonas aeruginosa in vitro and in an experimental tissue infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900145-4

7 January 2021

10.1016/S0924-8579(99)00145-4

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10720797